Sandoz, a Novartis (VTX: NOVN) division, has received approval from the European Commission (EC) for the use of Zessly (infliximab) in Europe, the company disclosed on Thursday.
Zessly blocks the action of tumour necrosis factor (TNF)-alpha in patients with certain autoimmune diseases where excess TNF-alpha activity can be harmful or cause the onset of disease. The drug inhibits an underlying cause of inflammation by blocking the action of TNF-alpha.
The EC has approved Zessly for use in all indications of the reference medicine, Remicade, which is marketed in Europe by MSD (NYSE: MRK) -- known as Merck in the US and Canada -- and is a registered trademark of Janssen Biotech Inc.
This means that Zessly has been approved as a treatment for diseases including rheumatoid arthritis, adult Crohn's disease, paediatric Crohn's disease, adult ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
The EC's approval was based on a review of a comprehensive development programme which including analytics, preclinical and clinical data. This confirmed that Zessly matched the reference medicine in terms of safety, efficacy and quality.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial